Company news

Frontier Biotechnologies Inc. news in 2026

Frontier Biotechnologies Inc.'s news releases, calls and decks from 2026, newest first.

View company

(688221)"Frontier Biotechnologies Inc."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

November 19, 2026

(688221)"Frontier Biotechnologies Inc."Announcement on Notifying Creditors of Using Reserve Funds to Make Up for Losses

November 19, 2026

(688221)"Frontier Biotechnologies Inc."Report for Q3 2026

October 30, 2026

(688221)"Frontier Biotechnologies Inc."Notice on Convening the 1st Extraordinary General Meeting in 2026

October 30, 2026

(688221)"Frontier Biotechnologies Inc."Announcement on Use of Reserve Funds to Make Up for Losses

October 30, 2026

(688221)"Frontier Biotechnologies Inc."Announcement on Convening the Q3 2026 Performance Briefing

October 30, 2026

Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares Reaching 1% and 5% Thresholds

September 29, 2026

Announcement on Return of Idle Raised Funds Temporarily Used to Supplement Working Capital

September 3, 2026

Announcement on Use of Temporarily Idle Raised Funds for Cash Management

August 30, 2026

Voluntary Disclosure Announcement on Obtaining Drug Registration Certificate for FB3002 Loxoprofen Sodium Patches

August 20, 2026

Indicative Announcement on Change in Equity of Shareholders Holding More Than 5% of the Shares Reaching 1% and 5% Threshold

August 12, 2026

Announcement on Returning Idle Raised Funds Used to Temporarily Supplement Current Capital

July 10, 2026

Announcement on Abnormal Fluctuations in Stock Trading

July 2, 2026

Announcement on Reply to the Supervision and Inquiry Letter Regarding Information Disclosure of the 2025 Annual Report

June 12, 2026

Announcement on Resolutions of the 2025 Annual General Meeting

May 22, 2026

Correction Announcement on Preliminary Earnings Estimate for 2025 and Earnings Preannouncement

April 24, 2026

Announcement on Changing the Disclosure Time of 2025 Annual Report and Report for Q1 2026

April 21, 2026

Announcement on Conducting Foreign Exchange Derivatives Trading Business

March 31, 2026

Announcement on Change of Scheduled Disclosure Time for Periodic Reports

March 30, 2026

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of FB7013 Injection

March 18, 2026

Announcement on Preliminary Earnings Estimate for 2025

February 27, 2026

Announcement on the Signing of an Authorization and License Agreement with GSK

February 23, 2026

Earnings Preannouncement for 2025

January 30, 2026

Announcement on Completing Industrial and Commercial Change Registration for Company Address Change and Issuance of New Business License

January 13, 2026

Announcement on Voluntary Disclosure of Acceptance Notice for the Clinical Trial Application for Domestic Production of Drugs of FB7013

December 31, 2025